Item talk:Q167209: Difference between revisions
From geokb
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{ | { | ||
" | "OpenAlex": { | ||
"cited_by_count": 1151188, | |||
"created_date": "2024-01-23", | |||
"description": "This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenstr\u00f6m macroglobulinemia.", | |||
"display_name": "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia", | |||
"domain": { | |||
"id": "https://openalex.org/domains/4", | |||
"display_name": "Health Sciences" | |||
}, | }, | ||
{ | "field": { | ||
"id": "https://openalex.org/ | "id": "https://openalex.org/fields/27", | ||
"display_name": " | "display_name": "Medicine" | ||
}, | }, | ||
{ | "id": "https://openalex.org/T11157", | ||
" | "ids": { | ||
" | "openalex": "https://openalex.org/T11157", | ||
"wikipedia": "https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia" | |||
}, | }, | ||
{ | "keywords": [ | ||
"id": "https://openalex.org/T10554", | "Chronic Lymphocytic Leukemia", | ||
"Genomic Aberrations", | |||
"BTK Inhibitors", | |||
"Rituximab", | |||
"Ibrutinib", | |||
"Prognostic Factors", | |||
"TP53 Mutation", | |||
"Waldenstr\u00f6m Macroglobulinemia", | |||
"Immunoglobulin Mutation", | |||
"Therapeutic Targets" | |||
], | |||
"siblings": [ | |||
{ | |||
"id": "https://openalex.org/T13738", | |||
"display_name": "CHARGE Syndrome and Related Genetic Disorders" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T12199", | |||
"display_name": "Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T12400", | |||
"display_name": "Gene Therapy for Spinal Muscular Atrophy" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T10554", | |||
"display_name": "Genetic and Clinical Aspects of Hemoglobin Disorders" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T10129", | |||
"display_name": "Gliomas" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T11917", | |||
"display_name": "Hereditary Angioedema: Molecular Mechanisms and Clinical Management" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T11628", | |||
"display_name": "Molecular Pathogenesis of Myeloproliferative Disorders" | |||
}, | |||
{ | |||
"id": "https://openalex.org/T10176", | |||
"display_name": "Multipotent Mesenchymal Stem Cells" | |||
} | |||
], | |||
"subfield": { | |||
"id": "https://openalex.org/subfields/2716", | |||
"display_name": "Genetics" | |||
}, | }, | ||
"updated_date": "2024-08-19T06:09:29.975916", | |||
"works_count": 87734, | |||
"oa_id": "T11157" | |||
} | |||
} | } |
Latest revision as of 21:11, 12 September 2024
{
"OpenAlex": { "cited_by_count": 1151188, "created_date": "2024-01-23", "description": "This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenstr\u00f6m macroglobulinemia.", "display_name": "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia", "domain": { "id": "https://openalex.org/domains/4", "display_name": "Health Sciences" }, "field": { "id": "https://openalex.org/fields/27", "display_name": "Medicine" }, "id": "https://openalex.org/T11157", "ids": { "openalex": "https://openalex.org/T11157", "wikipedia": "https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia" }, "keywords": [ "Chronic Lymphocytic Leukemia", "Genomic Aberrations", "BTK Inhibitors", "Rituximab", "Ibrutinib", "Prognostic Factors", "TP53 Mutation", "Waldenstr\u00f6m Macroglobulinemia", "Immunoglobulin Mutation", "Therapeutic Targets" ], "siblings": [ { "id": "https://openalex.org/T13738", "display_name": "CHARGE Syndrome and Related Genetic Disorders" }, { "id": "https://openalex.org/T12199", "display_name": "Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia" }, { "id": "https://openalex.org/T12400", "display_name": "Gene Therapy for Spinal Muscular Atrophy" }, { "id": "https://openalex.org/T10554", "display_name": "Genetic and Clinical Aspects of Hemoglobin Disorders" }, { "id": "https://openalex.org/T10129", "display_name": "Gliomas" }, { "id": "https://openalex.org/T11917", "display_name": "Hereditary Angioedema: Molecular Mechanisms and Clinical Management" }, { "id": "https://openalex.org/T11628", "display_name": "Molecular Pathogenesis of Myeloproliferative Disorders" }, { "id": "https://openalex.org/T10176", "display_name": "Multipotent Mesenchymal Stem Cells" } ], "subfield": { "id": "https://openalex.org/subfields/2716", "display_name": "Genetics" }, "updated_date": "2024-08-19T06:09:29.975916", "works_count": 87734, "oa_id": "T11157" }
}